Pair page
Enclomiphene Citrate with Triptorelin
Mechanism-tag overlap and published literature for Enclomiphene Citrate and Triptorelin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
selective-estrogen-receptor-modulatorserm
decapeptidegnrh-super-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Enclomiphene Citrate and Triptorelin have published these mechanism-level observations. Not a co-administration recommendation.
Selective estrogen receptor modulator used in post-AAS HPG-axis recovery. Blocks estrogen negative feedback at hypothalamus/pituitary, promoting LH/FSH. Often layered after a single-dose triptorelin restart in men's-health clinical protocols.
Quick facts
Enclomiphene Citrate
Triptorelin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2016 | Enclomiphene Citrate | Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. PMID: 26496621. (Pivotal Phase 3 RCT data.) PMID 26496621 | human trial, Phase 3 |
| — | Enclomiphene Citrate | ClinicalTrials.gov NCT01406964, NCT01403038 — Repros Phase 3 ZA-203 / ZA-204 trials. | human trial, Phase 3 |
| 2015 | Enclomiphene Citrate | Helo S, Ellen J, Mechlin C, Feustel P, Grossman M, Ditkoff E, McCullough A. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med. 2015;12(8):1761-1769. | human trial |
| 2019 | Enclomiphene Citrate | Earl JA, Kim ED. Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. 2019;14(3):157-165. (Modern clinical review.) | human study |
| 2018 | Enclomiphene Citrate | Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. | human study |
| 2016 | Enclomiphene Citrate | Pastuszak AW, Wiehle RD, Hsu K, Lipshultz LI. Enclomiphene Citrate for the Treatment of Secondary Male Hypogonadism. Expert Opin Investig Drugs. 2016;25(10):1233-1240. PMC5009465. (Comprehensive clinical review.) | human study |
| 2014 | Enclomiphene Citrate | Wiehle RD, Fontenot GK, Hsu K, Lipshultz L. Oral Enclomiphene Citrate Stimulates the Endogenous Production of Testosterone and Sperm Counts in Men with Low Testosterone: Comparison with Testosterone Gel. J Sex Med. 2014;11(5):1208-1218. | human study |
| 2013 | Enclomiphene Citrate | Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10(6):1628-1635. | human study |
| 2013 | Enclomiphene Citrate | Wiehle RD, Fontenot GK. Oral enclomiphene citrate lowers IGF-1 in men with secondary hypogonadism while raising testosterone: implications for cancer prevention. Cancer Res. 2013;73(8 Supplement):1326. (AACR abstract.) | human study |
| 2009 | Enclomiphene Citrate | Hill S, Arutchelvam V, Quinton R. Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. IDrugs. 2009;12(2):109-119. (Foundational enclomiphene clinical pharmacology paper.) | human study |
| 2003 | Enclomiphene Citrate | Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003;15(3):156-165. | human study |
| 2013 | Enclomiphene Citrate | Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. BJU Int. 2013;112(8):1188-1200. PMC4155868. (PK/PD study; 48 men; 6 weeks.) | pharmacology |
| 2011 | Triptorelin | Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostat… PMID 21788033 | human trial, Phase 3 |
| 2008 | Triptorelin | Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):15… PMID 19035858 | human trial, Phase 3 |
| 2005 | Triptorelin | Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20(5):1213-1220. PMID: 15689345. PMID 15689345 | human trial |
| 2006 | Triptorelin | Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N; Triptorelin 3-month CPP Study Group. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol. 2006;154(1):119-124. PMID: 16382001. PMID 16382001 | human study |
| 2003 | Triptorelin | Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC; South African Triptorelin Study Group. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003;92(3):226-231. PMID: 12887479. PMID 12887479 | human study |
| 2025 | Triptorelin | World Anti-Doping Agency. 2025 Prohibited List. Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. WADA, 2025. | regulatory / registry |
| — | Triptorelin | U.S. Food and Drug Administration. Trelstar (triptorelin pamoate for injectable suspension) Prescribing Information. Verity Pharmaceuticals. FDA.gov. | regulatory / registry |
| 2020 | Triptorelin | Lundy SD, Sabanegh ES Jr. Non-classical forms of male infertility: triptorelin in recovery of hypogonadotropic hypogonadism secondary to anabolic-androgenic steroid use. Transl Androl Urol. 2020;9(2):166-172. PMID: 32420127. PMID 32420127 | research article |
| 2015 | Triptorelin | Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al.; SOFT Investigators. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436-446. PMID: 25495490. PMID 25495490 | research article |
| 2012 | Triptorelin | Jungwirth A, Diemer T, Dohle GR, et al. European Association of Urology Guidelines on Male Infertility. Eur Urol. 2012;62(2):324-332. PMID: 22591628. PMID 22591628 | research article |
| 2010 | Triptorelin | Shore ND, Crawford ED. Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol. 2010;12(1):1-11. PMID: 20428290. PMID 20428290 | research article |
| 2007 | Triptorelin | Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007;3(2):157-167. PMID: 17237842. PMID 17237842 | research article |
Related pair pages
More research context
Frequently asked
Have Enclomiphene Citrate and Triptorelin been studied together?
Researchers have published mechanistic-level co-administration discussion of Enclomiphene Citrate and Triptorelin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Enclomiphene Citrate and Triptorelin share?
Enclomiphene Citrate and Triptorelin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Enclomiphene Citrate and Triptorelin?
Enclomiphene Citrate: CRL Dec 2015; not approved. Triptorelin: Approved (Trelstar, 2000). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Enclomiphene Citrate and Triptorelin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Enclomiphene Citrate profile and the Triptorelin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026